SMC-461
LGI1 Antibody, Clone N283/7
Cannot supply to this region.
- SKU:
- SMC-461
- Additional Names:
- LGI1, Leucine-rich glioma-inactivated protein 1, Epitempin 1, EPT, ETL1, ADLTE, ADPEAF, ADPAEF, IB1099, OTTHUMP00000020121, OTTHUMP00000020122
- Application:
- IHC, WB, IF, ICC
- Concentration:
- 1 mg/ml
- Species Reactivity:
- Mouse
- Purification:
- Protein G Purified
- Storage Conditions:
- -20[o]C
- Supplier:
- StressMarq Biosciences
- Host:
- Mouse
- Reactivities:
- Human, Mouse, Rat
- ABP:
- IMP-GEN-2015-06 < 10% Serum <100ml
- Buffer:
- PBS pH7.4, 50% glycerol, 0.1% sodium azide
- Immunogen:
- Fusion protein amino acids 37-113 (LRRNT domain and first LRR repeat) of mouse LGI1. Rat: 100% identity (77/77 amino acids identical). Human: 98% identity (76/77 amino acids identical). ~50% identity with LGI2, LGI3 and LGI4.
- Clone:
- N283/7 (Formerly sold as S283-7)
- Uniprot:
- Q9JIA1.1
- Synonyms:
- BB130740;leucine-rich glioma-inactivated protein 1
- Extra Details:
- LGI1 (Leucine-Rich Glioma Inactivated 1) is a secreted synaptic protein that modulates neuronal excitability and synaptic transmission. It interacts with ADAM22 and ADAM23 to stabilize AMPA receptor function and maintain synaptic integrity. Mutations in LGI1 are linked to autosomal dominant lateral temporal lobe epilepsy (ADTLE) and have been implicated in autoimmune encephalitis. In neurodegenerative disease research, LGI1 is gaining attention for its role in synaptic maintenance, neuroinflammation, and neuronal survival. Dysregulation of LGI1 may contribute to cognitive decline and seizure susceptibility. Its dual role in epilepsy and neurodegeneration highlights LGI1 as a valuable biomarker and therapeutic target in synaptic pathologies.
- Shipping Conditions:
- Blue Ice